Ménaché D
Rev Fr Transfus Immunohematol. 1985 Dec;28(6):643-58. doi: 10.1016/s0338-4535(85)80008-8.
PPSB, the plasma derivative which contains the vitamin K-dependent clotting factors, was first produced in 1959 at the Centre National de Transfusion Sanguine in Paris under the leadership of Jean-Pierre Soulier. Today over 20 such products are manufactured around the world. All production methods take advantage of the common adsorption and elution properties of all the vitamin K-dependent clotting factors due to the presence of gamma carboxy residues. Although the clinical use of PPSB has been extended to all congenital and acquired deficiencies of the vitamin K-dependent clotting factors and more recently to treat hemorrhagic episodes of hemophilia A patients with antibody to Factor VIII, the major clinical indication remains hemophilia B. The major complication associated with the use of PPSB is the occurrence of viral diseases, particularly non-A, non-B hepatitis of unknown etiology and specifically associated with the use of PPSB is the occurrence in some patients of thromboembolic complications. Current research is oriented toward the production of a safer product.
PPSB是一种含有维生素K依赖凝血因子的血浆衍生物，1959年在巴黎国家输血中心让 - 皮埃尔·苏利耶的领导下首次生产。如今，全球有20多种此类产品。由于存在γ-羧基残基，所有生产方法都利用了所有维生素K依赖凝血因子共同的吸附和洗脱特性。尽管PPSB的临床应用已扩展到所有先天性和获得性维生素K依赖凝血因子缺乏症，最近还用于治疗患有抗凝血因子VIII抗体的甲型血友病患者的出血发作，但主要临床适应症仍然是乙型血友病。与使用PPSB相关的主要并发症是病毒性疾病的发生，特别是病因不明的非甲非乙型肝炎，并且在一些患者中特别与PPSB相关的是血栓栓塞并发症的发生。目前的研究方向是生产更安全的产品。
